Evogene and Verb Biotics, a microbiome health ingredient company, entered into a collaboration agreement that will focus on the development of new strains of probiotic bacteria, which produce a highly sustainable quantity of microbial metabolites that improve human health and vitality. The collaboration will focus on identifying and enhancing the currently unknown genetic pathways in microbes that support the production of novel metabolites, using Evogene’s MicroBoost AI tech-engine and Verb Biotics’ extensive accumulated knowledge in the field of the microbiome. The probiotics market is expected to double and reach approximately $114B by 2031 from approximately $55B in 2022. The financial terms of the agreement are not disclosed.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
